Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Common Equity (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Common Equity data on record, last reported at $182.7 million in Q3 2025.

  • For Q3 2025, Common Equity rose 602.59% year-over-year to $182.7 million; the TTM value through Sep 2025 reached $182.7 million, up 602.59%, while the annual FY2024 figure was $33.4 million, 18.83% down from the prior year.
  • Common Equity reached $182.7 million in Q3 2025 per ASMB's latest filing, up from $18.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $247.2 million in Q1 2021 and bottomed at $18.1 million in Q2 2025.
  • Average Common Equity over 5 years is $99.5 million, with a median of $70.3 million recorded in 2023.
  • Peak YoY movement for Common Equity: plummeted 59.27% in 2023, then soared 602.59% in 2025.
  • A 5-year view of Common Equity shows it stood at $168.9 million in 2021, then plummeted by 51.07% to $82.7 million in 2022, then tumbled by 50.28% to $41.1 million in 2023, then dropped by 18.83% to $33.4 million in 2024, then surged by 447.66% to $182.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $182.7 million in Q3 2025, $18.1 million in Q2 2025, and $27.1 million in Q1 2025.